Tempus: Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a...

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances. LumiraDx’s transformative Point of Care solution will complement Roche’s diagnostics portfolio across Clinical...

PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...

Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline and Accelerate Global...

Source BioScience completes £18.5m strategic acquisition of LDPath Ltd to reimagine the future of pathology by combining cellular and digital pathology platforms Completes £18.5m strategic acquisition of LDPath Ltd Creates the largest...

In the wake of the news of Inspirata acquiring Omnyx recently I had an opportunity to speak with the CEOs of each company and get their thoughts. The big question in my mind and those of many readers was “Why Omnyx? Why now?” How did this...